ARID1A protein expression in endometriosis-associated ovarian carcinomas

Venni Yuliantini, Wresnindyatsih, Aida Farida, Zen Hafy
In: Journal of Physics: Conference Series · 2019 · vol. 1246(1) , pp. 012070 · doi:10.1088/1742-6596/1246/1/012070 · W2958425851
Observational OA: diamond CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

This study investigated ARID1A protein expression in Indonesian ovarian carcinomas, finding significantly lower expression in endometrioid and clear cell subtypes compared to serous subtypes, with no association to FIGO stage or histological grade.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-25 · read from full text ⓘ

This study analyzed ARID1A protein expression in archived tissue samples from 50 patients with various ovarian carcinomas, including endometrioid, clear cell, and serous subtypes. The researchers found that loss of ARID1A expression occurred significantly more frequently in endometrioid (27.3%) and clear cell carcinoma (62.5%) groups compared to the serous carcinoma group (8.7%). However, the analysis indicated that this protein loss was not associated with either the FIGO stage or the histological grade of the tumors within the respective groups. This paper is centrally about endometriosis — specifically examining the prevalence of ARID1A protein loss in endometriosis-associated ovarian carcinomas such as clear cell and endometrioid types.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Abstract Epithelial ovarian carcinoma is leading cause of death among gynaecologic malignancies. Somatic mutation of ARID1A gene often observed in endometriosis-associated ovarian carcinoma cases. This mutation causes loss of ARID1A protein expression on tumor-bearing tissues. This study aims to investigate ARID1A protein expression in endometriosis-associated ovarian carcinoma cases in Indonesia. The archive of Formalin-fixed paraffin embedded (FFPE) tissue of 11 endometrial carcinomas (EC), 16 clear cell carcinoma (CCC), and 23 serous carcinomas (SC) from January 1, 2016, to December 31, 2017. The ARID1A expression were analyzed by using Kolmogorov Smirnov and Fisher’s Exact Tests. Majority of patients were older than 50 years (90%). Loss of ARID1A expression in tumor tissue was significantly low in the SC group (8.7%) compared to the EC group (27.3%) and the CCC group (62.5%) (p = 0.021). This study showed that ARID1A expression, was not associated with FIGO stage (p = 0,423), and with histological grade of the cases in EC group (p = 0,544) and SC group (p = 0,395). Loss of ARID1A expression was more frequently found in EC and CCC cases. Loss of ARID1A expression was not associated with FIGO stage and histological grade.
Full text 1,477 characters · extracted from oa-doi-fallback · click to expand
Abstract Epithelial ovarian carcinoma is leading cause of death among gynaecologic malignancies. Somatic mutation of ARID1A gene often observed in endometriosis-associated ovarian carcinoma cases. This mutation causes loss of ARID1A protein expression on tumor-bearing tissues. This study aims to investigate ARID1A protein expression in endometriosis-associated ovarian carcinoma cases in Indonesia. The archive of Formalin-fixed paraffin embedded (FFPE) tissue of 11 endometrial carcinomas (EC), 16 clear cell carcinoma (CCC), and 23 serous carcinomas (SC) from January 1, 2016, to December 31, 2017. The ARID1A expression were analyzed by using Kolmogorov Smirnov and Fisher’s Exact Tests. Majority of patients were older than 50 years (90%). Loss of ARID1A expression in tumor tissue was significantly low in the SC group (8.7%) compared to the EC group (27.3%) and the CCC group (62.5%) (p = 0.021). This study showed that ARID1A expression, was not associated with FIGO stage (p = 0,423), and with histological grade of the cases in EC group (p = 0,544) and SC group (p = 0,395). Loss of ARID1A expression was more frequently found in EC and CCC cases. Loss of ARID1A expression was not associated with FIGO stage and histological grade. Content from this work may be used under the terms of the Creative Commons Attribution 3.0 licence. Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (28)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK